What is B. Riley’s Estimate for VKTX Q4 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at B. Riley issued their Q4 2024 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research report issued to clients and investors on Thursday, November 21st. B. Riley analyst M. Mamtani anticipates that the biotechnology company will earn ($0.24) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

VKTX has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Tuesday. Morgan Stanley reaffirmed an “overweight” rating and set a $105.00 price target on shares of Viking Therapeutics in a report on Thursday, September 12th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Oppenheimer restated an “outperform” rating and issued a $138.00 target price on shares of Viking Therapeutics in a research report on Wednesday, September 25th. Finally, StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $109.73.

Viking Therapeutics Stock Performance

Shares of VKTX stock opened at $53.42 on Monday. Viking Therapeutics has a 52 week low of $11.55 and a 52 week high of $99.41. The company has a market capitalization of $5.95 billion, a price-to-earnings ratio of -57.44 and a beta of 1.00. The company has a 50-day simple moving average of $63.43 and a 200 day simple moving average of $60.05.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. During the same period in the prior year, the business posted ($0.23) earnings per share.

Insider Activity at Viking Therapeutics

In related news, CEO Brian Lian sold 216,130 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the completion of the sale, the chief executive officer now owns 2,304,927 shares in the company, valued at approximately $163,257,979.41. This represents a 8.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director J Matthew Singleton sold 10,300 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $69.50, for a total transaction of $715,850.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at approximately $660,250. The trade was a 52.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 371,117 shares of company stock worth $27,140,009 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VKTX. Signaturefd LLC grew its position in Viking Therapeutics by 16.2% during the third quarter. Signaturefd LLC now owns 1,351 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 188 shares during the period. Stone House Investment Management LLC increased its stake in shares of Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Keudell Morrison Wealth Management lifted its stake in Viking Therapeutics by 5.9% in the third quarter. Keudell Morrison Wealth Management now owns 4,306 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 241 shares during the last quarter. GAMMA Investing LLC increased its position in Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after buying an additional 243 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its position in shares of Viking Therapeutics by 84.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 253 shares during the period. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.